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Preexisting Antibody-Dependent
Cellular Cytotoxicity–Activating
Antibody Responses Are Stable
Longitudinally and Cross-reactive
Responses Are Not Boosted by Recent
Inﬂuenza Exposure
Sophie A. Valkenburg,1,2 Yanyu Zhang,2 Ka Y. Chan,2 Kathy Leung,2 Joseph T. Wu,2 and
Leo L. M. Poon2
1HKU-Pasteur Research Pole, and 2School of Public Health, University of Hong Kong
Cross-reactive inﬂuenza virus–speciﬁc antibody-dependent cel-
lular cytotoxicity (ADCC)–activating antibodies are readily de-
tected in healthy adults. However, little is known about the
kinetics of these ADCC responses. We used retrospective serial
blood samples from healthy donors to investigate this topic. All
donors had ADCC responses against 2009 pandemic inﬂuenza
A(H1N1) virus (A[H1N1]pdm09) and avian inﬂuenza
A(H7N9) virus hemagglutinins (HAs) despite being seronega-
tive for these viruses in standard hemagglutination inhibition
and microneutralization serological assays. A(H1N1)pdm09
exposure did not boost ADCC responses speciﬁc for H7 HA
antigens. H7 HA ADCC responses were variable longitudinally
within donors, suggesting that these cross-reactive antibodies
are unstable. We found no correlation between ADCC respons-
es to the H7 HA and either inﬂuenza virus–speciﬁc immuno-
globulin G1 concentration or age.
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In 2009, a novel strain of inﬂuenza A(H1N1)pdm virus
emerged that rapidly spread worldwide, causing the ﬁrst inﬂu-
enza pandemic of this century. Older adults were partly protect-
ed from the disease because of preexisting immunity, whereas
younger adults and children were more readily infected.
Owing to the unique hemagglutinin (HA) head of the 2009
virus, vaccination or infection in some adults boosted antibody
responses to conserved epitopes of the functionally conserved
HA stem [1]. More recently, in 2013, a novel inﬂuenza
A(H7N9) virus emerged in China, resulting in >781 cases and
313 deaths [2]. Unlike seasonal A(H1N1) and inﬂuenza
A(H3N2) virus, the H7 subtype still cannot cause sustainable
transmissions in humans, and the great majority of the popula-
tion is immunologically naive to this newly emerged virus.
Thus, the frequent occurrence of human cases of A(H7N9) in-
fection continues to be a major public health emergency of pan-
demic concern.
Growing evidence suggest that a signiﬁcant portion of
healthy individuals carry nonneutralizing antibodies that
are cross-reactive with inﬂuenza viruses of multiple subtypes
[3, 4]. Such antibodies can be used by the innate and adaptive
immune system synergistically to ﬁght viral infection through
antibody-dependent cellular cytotoxicity (ADCC). ADCC-
activating antibodies cross-link virus-infected cells and Fc
receptors of CD16+/CD32+/CD64+ cells, such as B cells, neutro-
phils, macrophages, and natural killer (NK) cells. ADCC activa-
tion of NK cells results in degranulation and the release of
preformed cytotoxic granules and proinﬂammatory antiviral
cytokines. Thus, ADCC could have a protective role against
inﬂuenza virus infection.
Previously, ADCC-activating antibodies speciﬁc for H5 HA
were detected in healthy individuals without prior inﬂuenza
A(H5N1) virus exposure. In addition, a correlation with
ADCC responses and reduced disease severity with increased
age was found for adults aged >45 years prior to the 2009 pan-
demic due to inﬂuenza A(H1N1) virus (A[H1N1]pdm09),
whereas A(H1N1)pdm09-speciﬁc ADCC responses were boost-
ed in individuals aged 15–45 years following exposure during the
course of the pandemic [5].
The presence of broadly cross-reactive inﬂuenza virus–speciﬁc
antibodies has ignited an interest in universal antibody-based
vaccines that could able to recruit other immune cells. However,
much remains to be deciphered about inﬂuenza virus–speciﬁc
ADCC responses. In this study, we report the stability of
ADCC responses over the long term in serial blood donors
and the high baseline magnitude of responses toward different
inﬂuenza virus proteins within the same individual, before and
after A(H1N1)pdm09 exposure.
Prior to the 2009 pandemic, the population was predomi-
nantly serologically naive to the novel virus, resulting in the
rapid global spread of A(H1N1)pdm09. Infection with or vac-
cination against A(H1N1)pdm09 in some individuals elicited
broadly reactive antibodies, owing to the heterologous nature
of H1 HA. We aimed to investigate the relationship of
A(H1N1)pdm09 and cross-reactive avian inﬂuenza virus–
speciﬁc ADCC-activating antibodies. Therefore, we probed for
H7 HA avian-speciﬁc ADCC-activating antibody responses in
healthy individuals in Hong Kong, a community which is sero-
logically naive to A(H7N9) in China, and for which A(H7N9)
remains a public health threat. Furthermore, as H7 is a group 2
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HA subtype, there is less cross-reactivity with existing group 1
HA responses for H1 and H5 viruses. The conserved nucleopro-
tein (NP) was included in our study as an internal control be-
tween H1 HA and H7 HA. Furthermore, mouse studies have
shown a protective role of NP-speciﬁc nonneutralizing antibod-
ies upon adoptive transfer [6, 7]. Therefore, NP-speciﬁc ADCC
activity could be a potential immune correlate for inﬂuenza
virus infection. Thus, we hypothesized that A(H1N1)pdm09 ex-
posure could increase ADCC responses to divergent inﬂuenza
viruses, such as avian A(H7N9), owing to boosting of antibodies
to conserved epitopes, like the HA stem.
METHODS
Subjects and Samples
All serum samples were derived from samples collected from
blood donors at the Hong Kong Red Cross Blood Transfusion
Services from June 2009 to June 2010. Longitudinal samples
from repeat blood donors were collected at multiple time points,
with 2–6 months (median time, 4 months) between consecutive
donations. Paired or serial samples were collected from donors
with 2 (n = 10), 3 (n = 5), or 4 (n = 2) blood donations within
the studied period. Exposure to A(H1N1)pdm09 (A/Califor-
nia/07/2009) was determined by standard hemagglutination in-
hibition (HAI) and microneutralization (MN) assays [8].
A(H1N1)pdm09 exposure was deﬁned as a MN titer of≥ 1:40
and a HAI titer of≥ 1:40, and A(H1N1)pdm09-negative donors
were deﬁned as individuals with a MN titer of < 1:20. All serum
was frozen and heat inactivated at 56°C for 60 minutes before
use. Serum for HAI and MN assays was also treated with recep-
tor-destroying enzyme.
Protein-Speciﬁc ADCC Responses
A protein plate-bound NK ADCC assay was adopted from
Jegaskanda et al [9]. The assay measures degranulation
(CD107a) and antiviral (interferon γ [IFN-γ]) function of
human NK cells due to cross-linking of inﬂuenza virus–speciﬁc
immunoglobulin G (IgG) in donor sera. Brieﬂy, U-bottomed
enzyme-linked immunosorbent assay (ELISA) plates are coated
overnight with recombinant inﬂuenza virus proteins, H7 HA
(H7N9; A/Anhui/01/2013), H1 HA (H1N1; A/California/04/
2009), and NP (H7N9; A/Anhui/01/2013; >95% homology
with H1N1-derived NP; 400 ng/well; SinoBiological) in phos-
phate-buffered saline (PBS). Background ADCC activity by
NK cells was determined by analysis of paired serum specimens
with plate-bound nonspeciﬁc protein (allantoic ﬂuid), with
positive controls including puriﬁed CD16 antibody (Biolegend)
for coating and pooled human sera (n = 4 donors pooled) tested
against each protein.
Fresh peripheral blood mononuclear cells (PBMCs) from a
healthy donor were isolated by Ficoll-Paque density gradient
centrifugation on the day of the experiment. Protein-bound
plates were thoroughly washed, and heat-inactivated immune
serum was allowed to bind for 2 hours at 37°C. Plates were
then further washed and incubated with PBMCs (2–5 × 105
cells) in the presence of brefeldin A/monensin and anti-
human CD107a-APC. After 5 hours, cells were stained with
anti-human CD14-PerCPCy5.5, CD3-APCCy7, and CD56-PE
(Biolegend) in ﬂuorescence-activated cell-sorting buffer (PBS
with 1% fetal bovine serum and 0.1% sodium azide). Cells
were then ﬁxed (BD Cytoperm/cytoﬁx buffer) and stained
with anti-human IFN-γ–FITC (Biolegend) in BD Perm Wash
buffer and then acquired on an LSR Fortessa.
ELISA
Brieﬂy, recombinant inﬂuenza virus proteins (H1 HA, H7 HA,
and NP, as described above; 80 ng/mL; SinoBiological) were
coated on ELISA plates (Nunc-Immuno MaxiSorp, NUNC)
overnight. After plates were blocked with fetal bovine serum
and washed, diluted serum samples (1:10) were bound for
2 hours, washed, and detected by mouse anti-human IgG1–
horseradish peroxidase (BD Biosciences) as the secondary
antibody. TMB/peroxide was used as substrate, the reaction
was stopped by addition of sulfuric acid (R&D systems), and
absorbance was read at 450 nm.
RESULTS
A(H1N1)pdm Seroconversion Does Not Correlate With Increased H7 HA
ADCC Responses
To determine whether A(H1N1)pdm09 exposure increased in-
ﬂuenza virus–speciﬁc ADCC, serum from A(H1N1)pdm09-
positive and A(H1N1)pdm09-negative donors was tested for
ADCC responses to H7 HA, H1 HA, and NP (Figure 1). Re-
sponses by total ADCC (CD107a+ and/or IFN-γ+; Figure 1B)
and IFN-γ+ (Figure 1C) were comparable. These observations
were further conﬁrmed by using diluted sera (1:20; data not
shown). Overall, there was no signiﬁcant difference in ADCC
responses or different proteins between A(H1N1)pdm09-
positive and A(H1N1)pdm09-negative donors. However, the
response magnitude was protein dependent, with an immuno-
dominance hierarchy of H1 HA, NP, and then H7 HA.
Paired serum from the same donor before and after A(H1N1)
pdm09 infection was again compared across H7 HA, H1 HA,
and NP (Figure 2). Again there was no consistent increase in
the ADCC response magnitude after recent A(H1N1)pdm09
exposure. For H1 HA, 4 donors had reduced ADCC responses
after exposure, 3 had increased responses, and responses in 3
remained unchanged (Figure 2A), whereas for H7 HA, 3 donors
had reduced ADCC responses after exposure, 3 had increased
responses, and responses in 5 remained unchanged. NP-speciﬁc
ADCC responses were reduced in all 10 donors after A(H1N1)
pdm09 exposure but were within a close range of their original
baseline responses.
Further comparison of the stability of ADCC responses
longitudinally over 3–4 time points for repeated blood donors
(Figure 2B–D) showed again that A(H1N1)pdm09 seroconversion
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did not result in increased H1 HA responses. H1 HA–speciﬁc
ADCC responses were stable from 2 to 6 months between blood
donations. Similarly, NP-speciﬁc ADCC responses were stable,
whereas cross-reactive H7 HA ADCC responses showed higher
levels of variation within donors longitudinally (Figure 2C). Inter-
estingly, a substantial decrease in the ADCC response against H7
HA was detected in these individuals at the time when they were
found to have seroconverted to A(H1N1)pdm09.
ADCC Responses Do Not Correlate With Increased Age or IgG Antibody
Concentration
H1 HA–, H7 HA–, and NP-speciﬁc antibodies were further as-
sessed by quantiﬁcation of their concentration, using IgG1
ELISA (Supplementary Figure 1). Levels of H1 HA IgG1 anti-
bodies were increased in A(H1N1)pdm09-positive subjects,
whereas levels of H7 HA– and NP-speciﬁc IgG1 were un-
changed (Supplementary Figure 1A). Again there was no differ-
ence in H7 HA–speciﬁc IgG1 levels after A(H1N1)pdm09
exposure in either prepandemic and postpandemic community
samples (Supplementary Figure 1A) or in donor paired samples
(Supplementary Figure 1B). Furthermore, longitudinal serum
samples did not show a rise in H7 HA antibodies after
A(H1N1)pdm09 exposure. NP IgG levels had similar results.
Overall, there was no increase in H7 HA IgG antibody levels
or ADCC responses among individuals with A(H1N1)pdm09
seroconversion.
A(H1N1)pdm09-positive and A(H1N1)pdm09-negative do-
nors (Figure 1B) were assessed for correlation between age and
the magnitude of the ADCC response to multiple inﬂuenza
virus proteins (Supplementary Figures 2A and 2B). No signiﬁ-
cant correlation was found between increased age and the mag-
nitude of the ADCC responses. In addition, there was no
correlation with NP-speciﬁc IgG1 and NP-speciﬁc ADCC re-
sponses in A(H1N1)pdm09-positive donors (R2 = 0.23; Supple-
mentary Figure 2C). These results are in agreement with our
lack of correlation for increased ADCC response and recent
A(H1N1)pdm09 infection.
DISCUSSION
High-level baseline responses were found in our Hong Kong
study cohort for H1 HA and H7 HA in healthy unexposed sub-
jects. Recently, high levels of A(H7N9) and A(H5N1) ADCC-
activating and complement-ﬁxing antibodies were found in all
US infants and adults aged ≥8 years [10].Conversely, in an Aus-
tralian study, when individual donor serum was tested, only 1 of
69 adult donors had A(H7N9)-speciﬁc ADCC-activating anti-
bodies, with antibody levels increasing after the 2009 pandemic
Figure 1. Influenza A(H1N1)pdm09 virus seroconversion does not correlate with increased anti–influenza virus antibody-dependent cellular cytotoxicity (ADCC) responses in
the community. A, Representative fluorescence-activated cell-sorting plots show the amount of ADCC (in bold) as the summed total of CD107a+ and/or interferon γ (IFN-γ)+
natural killer (NK) cells (CD14−CD3−CD56+). B and C, A(H1N1)pdm09 microneutralization (MN) assay positive (n = 17; black symbols), MN assay negative (n = 15; white sym-
bols), and pooled serum (pooled from 4 Red Cross blood donors after the pandemic; gray symbols) were assessed for ADCC-activating antibody responses toward the H1
hemagglutinin (HA), H7 HA, and conserved nucleoprotein (NP). The amount of ADCC is the summed total of CD107a+ and/or IFN-γ+ (B) or IFN-γ+ (C) NK cells.
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[11]. Furthermore, Australian intravenous immunoglobulin
preparations (antibody preparations pooled from thousands
of donors) contained ADCC-activating antibodies for H1, H2,
H3, H4, H5, and H7 [11]. However, the H7N9-Anhui/01/2013
ADCC responses were very low in IVIG preparations, compared
with other HA subtypes, and ADCC responses against other
A(H7N9) variants (A/Shanghai/01/2013 and A/Hangzhou/01/
2013) were at even lower background levels. Our results are con-
sistent with those of the recent US study in that all adults had
cross-reactive avian-speciﬁc ADCC-activating antibodies.
Figure 2. Longitudinal stability of anti-influenza virus antibody-dependent cellular cytotoxicity (ADCC) responses is protein specific. A, Paired sera from the same donor
(n = 10) before and after influenza A(H1N1)pdm virus exposure (confirmed A[H1N1]pdm positivity was defined as a microneutralization [MN] titer of > 1:40 and a hemagglu-
tination inhibition titer of > 1:40) was assessed for ADCC toward H1 hemagglutinin (HA), H7 HA, and nucleoprotein (NP). Serial longitudinal serum of donors positive for
A(H1N1)pdm09 by MN assay (before and after A[H1N1]pdm seroconversion) from 3 (n = 5) and 4 time points (n = 2) were tested for the magnitude of the ADCC response
to H1 HA (B), H7 HA (C), and NP (D). The amount of ADCC is the summed total of CD107a+ and/or interferon γ+ cells. Individual responses are given. Red symbols indicate
the point of A(H1N1)pdm09 seroconversion, based on MN findings. Time points are intervals between Red Cross blood donations, which are 2–6 months (median, 4 months).
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In our study, A(H1N1)pdm09-exposed donors showed no
increase in H1 HA ADCC–activating antibodies following ex-
posure to A(H1N1)pdm09. This is most likely attributed to
the high-level baseline H1 HA ADCC responses that cross-
react with previous seasonal A(H1N1) exposure. Previously,
an age-related increase was found for H1 HA ADCC response
prior to the 2009 pandemic [5], whereby adults aged <45 years
had reduced ADCC activity, which normalized after the pan-
demic. We did not ﬁnd a signiﬁcant correlation with age and
H1 HA–, H7 HA–, or NP-speciﬁc ADCC-activating antibodies,
whereas the recent US ADCC study found a correlation
(R2 = 0.46) between age (1–18 years) and A(H7N9)-speciﬁc
ADCC activity [10]. Importantly, their donors were children,
whereas our cohorts comprise adults aged 17–55 years. Previous
data reported by Jegaskanda et al [3, 12] from studies of ma-
caque models show that vaccination with inactivated inﬂuenza
virus vaccines does not elicit detectable ADCC responses but
that A(H1N1)pdm09 challenge of vaccinated macaques recalls
a homologous H1 HA–speciﬁc ADCC response [3, 12]. Ma-
caque inﬂuenza virus–speciﬁc ADCC responses are mounted
early after infection, wane in magnitude, and remain stable to
memory time points. Naive animal models and infants (age,
<2 years) demonstrate an induction of inﬂuenza virus–speciﬁc
ADCC responses after inﬂuenza exposure. Therefore, it is pos-
sible that ADCC activity reaches a ceiling threshold in adults
and that ADCC responses are accumulated after seasonal inﬂu-
enza exposure up to an immune ceiling. This would explain
why we found a high baseline ADCC responses and no boosting
effect after recent exposure in adults, as ADCC responses had
already reached a threshold level.
In our study, the magnitude of ADCC responses toward H1
HA and NP was relatively stable before, immediately after, dur-
ing the 6 months following A(H1N1)pdm09 seroconversion in
our 7 donors tested longitudinally. However, H7 HA ADCC re-
sponses were more variable with time and between donors,
making the kinetics and stability of cross-reactive H7N9
ADCC responses unclear. The same donor could show high-
level responses and, at the next time point, have a response
that had decreased to lower levels. Future vaccine strategies
should aim to establish and stabilize avian inﬂuenza virus–
speciﬁc ADCC responses to ensure this emerging immune
correlate is used.
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